Investors & Media

Press Releases

Press Releases

Date Title View
Toggle Summary Sage Therapeutics to Present at Goldman Sachs 41st Annual Global Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 1, 2020-- Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present
View HTML
Toggle Summary Sage Therapeutics to Present at Bank of America Health Care Conference 2020
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 8, 2020-- Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present at
View HTML
Toggle Summary Sage Therapeutics Announces First Quarter 2020 Financial Results and Highlights Pipeline and Business Progress
Expected initiation of three new short-term zuranolone clinical studies in 2020, with the potential for three distinct indications April restructuring to advance corporate strategy and pipeline expected to result in approximate annualized cost savings of $170M , with significant portion related to
View HTML
Toggle Summary Sage Therapeutics to Report First Quarter 2020 Financial Results on Thursday, May 7, 2020
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 16, 2020-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced it will host a live webcast
View HTML
Toggle Summary Sage Therapeutics Announces Restructuring to Advance Corporate Strategy and Pipeline
Changes are expected to result in annualized cost savings of approximately $170 million , including SG&A savings of $150 million Headcount reduction of 340 – approximately 53 percent of workforce Current balance of cash, cash equivalents, restricted cash, and marketable securities expected to
View HTML
Toggle Summary Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 3, 2020-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that on April 1, 2020 , the
View HTML
Toggle Summary Sage Therapeutics Announces Development Plan for Zuranolone (SAGE-217) Following Breakthrough Therapy Guidance Meeting with the U.S. Food & Drug Administration
Expected regulatory pathway for episodic treatment of major depression remains unchanged with plan for one new additional efficacy study Pursuing two additional pathways with the goal of accelerating patient access to zuranolone while continuing development for the episodic treatment of depression
View HTML
Toggle Summary Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that on March 2, 2020 , the Compensation
View HTML
Toggle Summary Sage Therapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Highlights Pipeline and Business Progress
ZULRESSO™ (brexanolone) CIV injection net revenues of $2M and $4M for fourth quarter and full year 2019, respectively Evaluating path forward for the zuranolone (SAGE-217) Landscape Program Continued expansion of Neurology and Neuropsychiatry franchises with planned initiation of additional
View HTML
Toggle Summary Sage Therapeutics to Present at the Cowen & Co. 40th Annual Health Care Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 24, 2020-- Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present at
View HTML